Phathom Pharmaceuticals
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Phathom Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
Phathom Pharmaceuticals: 13 sponsored US clinical trials, 2 recruiting.
Phathom Pharmaceuticals sponsors 13 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 11 completed. 3 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Symptomatic Non-erosive Gastroesophageal Reflux Disease, with 1 trials.
Top-decile sponsor footprint
Phathom Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
13 total, page 1 of 1
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
NCT06851559
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
NCT06660342
A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants
NCT06831344
A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily
NCT06391177
A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease
NCT06106022
A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants
NCT05366738
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease
NCT05343364
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
NCT05195528
A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
NCT04799158
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants
NCT04729101
Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants
NCT04545944
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection
NCT04167670
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis
NCT04124926
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 2 |
| Phase 3 | 3 |
What is open in the Phathom Pharmaceuticals pipeline
2 recruiting of 13 indexed (15% open); 11 completed (85%).
Phase mix: 3 late (III/IV) vs 9 early (I/II) (early-phase heavy).
Top condition: Symptomatic Non-erosive Gastroesophageal Reflux Disease (1 trial), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Phathom Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 13 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Phathom Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 trials (± recruiting share)
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Arrowhead Regional Medical Center · 15% recruiting · 13 trials
- Aurinia Pharmaceuticals · 15% recruiting · 13 trials
- Bronx VA Medical Center · 15% recruiting · 13 trials
- Candel Therapeutics · 15% recruiting · 13 trials
Related
What to do with this Phathom Pharmaceuticals page
13 registered trials is a research-attention snapshot, not an endorsement of Phathom Pharmaceuticals or any single study.
- 2 of Phathom Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Symptomatic Non-erosive Gastroesophageal Reflux Disease is the condition Phathom Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Symptomatic Non-erosive Gastroesophageal Reflux Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Phathom Pharmaceuticals pipeline card: 13 registered trials from official public datasets.Report a data error.